Agios reports data from phase 1 dose-escalation study of AG-881
Agios reported updated data from the ongoing Phase 1 study evaluating single agent AG-881 in advanced glioma. AG-881 is an investigational, oral, selective, potent inhibitor of the mutant IDH1 and IDH2 enzymes and was designed for enhanced brain penetrance for development in IDH-mutant glioma. November 16, 2018